Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07218341 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

StatusRecruiting
PhasePhase 4
Started2026-03-09
View on ClinicalTrials.gov ↗
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Amendment history 3 changes detected by DataLookout

2026-07-21
Trial sites reduced: 53 → 50 locations
2026-04-18
Recruitment opened
2026-04-18
Trial sites expanded: 50 → 53 locations
Trial Details
NCT Number NCT07218341
Lead Sponsor Eli Lilly and Company
Conditions Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Enrollment 150 participants
Start Date 2026-03-09
Primary Completion 2030-05 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-04